Blake Insomnia is trying to get a beta blocker approved as a pharmaceutical grade sleeping aid for individuals suffering from stress-induced insomnia, reports TalkMarkets.
Blake Insomnia has taken a beta blocker called Nebivolol, and it is this drug that forms the core active ingredient of ZLX-1. Nebivolol is a ?1 receptor blocker that induces what’s called a nitric oxide-potentiating vasodilatory effect. Being a ?1 receptor blocker means it is selective to this receptor (?1), and doesn’t block ?2 receptors. The vast majority of the side effects associated with standard of care beta blockers (Propranolol, Carteolol, Bucindolol, etc.) derive from the active ingredient’s blocking of the ?2 receptor. Included in this “vast majority” is the inhibition of melatonin, and in turn, the sleep issues and daytime fatigue associated with ?2 receptor blockers.
